Inhibition of IL-1β improves fatigue in type 2 diabetes

Diabetes Care

Volumn 34, Issue 10, 2011, Pages

  Cavelti Weder, Claudia ^a   Furrer, Romana ^a   Keller, Cornelia ^a   Babians Brunner, Andrea ^a   Solinger, Alan M ^b   Gast, H ^c   Fontana, A ^d   Donath, Marc Y ^a   Penner, Iris K ^e  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b XOMA (US)   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GEVOKIZUMAB; GLUCOSE; HEMOGLOBIN A1C; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; PLACEBO; MONOCLONAL ANTIBODY;

BODY TEMPERATURE MEASUREMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FATIGUE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RELEASE; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT DURATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; METABOLISM; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; HUMANS; INTERLEUKIN-1BETA;

EID: 84860805156     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1196     Document Type: Letter

References (5)

1. Cavadini G, Petrzilka S, Kohler P, et al. TNF-alpha suppresses the expression of clock genes by interfering with E-boxmediated transcription. Proc Natl Acad Sci USA 2007;104:12843-12848 (Pubitemid 47255242)
2. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-1526 (Pubitemid 46588416)
3. Rissanen A, Howard C, Botha J, Thuren T. IL-1β antibody (canakinumab) improves insulin secretion rates in subjects with impaired glucose tolerance (IGT) and type 2 diabetes (T2DM). Late breaking abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, San Diego Convention Center, San Diego, California
4. Donath MY, Weder C, Whitmore J, et al. XOMA 052, an anti-IL-1β antibody, in a double blind, placebo controlled, dose escalation study of the safety and pharmacokinetics in patients with type 2 diabetes mellitus - a new approach to therapy. Diabetologia 2008;51(Suppl. 1):A1
5. Penner IK, Raselli C, Stöcklin M, Opwis K, Kappos L, Calabrese P. The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler 2009;15:1509-1517